×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Articles

Brielle Urciuoli
Immunotherapy is being tested in the second-line setting for metastatic bladder cancer. Pending trial results, the role of chemotherapy for this patient population may change.
Brielle Urciuoli
CURE spoke with the chief medical officer of the Leukemia & Lymphoma Society to hear what she thinks are important next steps in improving patient outcomes.
Brielle Urciuoli
An MPN diagnosis can be overwhelming, but here are some of the basic facts every newly diagnosed patient should know.
Kristie L. Kahl
According to findings from the ASCO Annual Meeting, insurance disparities still exist, and may even contribute to cancer-specific and comorbidity-associated mortalities in patients with early-stage non-small cell lung cancer.
Kristie L. Kahl
Phase 2 study results showed that patients with metastatic or unresectable, FGFR-positive bladder cancer may have a third-line option for treatment.
Silas Inman
The FDA has incorporated PD-L1 status into the labels for Keytruda (pembrolizumab) and Tecentriq (atezolizumab) for existing frontline approvals for platinum-ineligible patients with urothelial carcinoma, based on lower overall survival (OS) rates with the PD-1/PD-L1 inhibitors compared with platinum-based chemotherapy for patients with PD-L1–low expressing platinum-eligible urothelial carcinoma.
Katie Kosko
Treatment with chimeric antigen receptor (CAR)-T cell therapy showed encouraging rates of durable responses among adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), according to updated data from the pivotal JULIET trial.
 
Brielle Urciuoli
Dewayne Johnson is the first of hundreds of patients to take Monsanto to trial, claiming that Roundup caused them to get cancer. His case will be seen even sooner than others because in California dying plaintiffs can be given expedited trials.
The campaign highlights patients achieving lifelong goals and everyday tasks during their cancer journey
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

In Treatment

Maintenance/Hormone Treatment

Out of Treatment

Caregiver

Healthcare Professional

Not Applicable